data were presented today during a late-breaking presentation (OA06.03) and included as part of the press program at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25). Ifinatamab...
need, announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025, titled “Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B Virus...
and approved by leading global regulatory agencies including the USFDA, PMDA (Japan), and CDSCO (India). As of March 2025, Sai Life Sciences’ manufacturing units had undergone over 75 customer audits in the past three years, reflecting its...
virkningsmekanisme. Studiet forventes at inkludere 32 patienter, hvor den første patient forventes inkluderet i 4. kvartal 2025. ”Myndighedsgodkendelsen af vores RNX-011-studie er en afgørende kommerciel milepæl for Pharma Equity Group. Vi tager nu...
In the IIT, the patient began with a baseline hemoglobin level of 67.3 g/L. Following CS-101 treatment in February 2025, she achieved rapid hematopoietic recovery, with neutrophil engraftment in 13 days and platelet counts surpassing 50×10⁹/L in 21...
the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated:...
Breakthrough Data Validates its Dual-immune Activation Mechanism, Stepwise Development in Multiple Tumor Types: At ASCO 2025, Phase 1b/2 results demonstrated meaningful and durable clinical activity in areas of high unmet need, including...
rhCollagen for tissue regeneration and medical aesthetics, announced financial results for the second quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "In recent months, CollPlant has been...
by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses...
any artificial additives. The results of this study—drawn from a double-blind national survey of U.S. pediatricians (FRC 2025) — found that an overwhelming majority of respondents prefer Genexa’s oral suspension ingredient profiles for treating...
upon commercial marketing of the medicine. Venofer® had annual sales of approximately $515M in the U.S. as of June 30, 2025, according to IQVIA. Iron Sucrose Injection, For Intravenous Use INDICATION AND USAGE Iron sucrose injection is indicated...
following radiotherapy.6 Modeyso was developed by Chimerix prior to its acquisition by Jazz Pharmaceuticals in April 2025. DRUG INTERACTIONS Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of MODEYSO with strong and moderate CYP3A4...
USP in the United States as a therapeutic generic equivalent of Ablysinol®, which ended its market exclusivity in June 2025. Dehydrated Alcohol Injection is indicated to induce controlled cardiac septal infarction to improve exercise capacity in...
marks our fifth product launch this year, expanding our portfolio to twenty-five products with several more planned for 2025 and beyond," said Vimal Kavuru, Chairman & CEO. This launch enhances Cronus Pharma's robust sedative and anesthesia product...
strategy leveraging TrueMed's digital authentication technology to identify and act on threats instantly. "You can't fight 2025 counterfeits with 2010 tools," said Jyrki Berg, CEO of TrueMed. "Our collaboration with Alliance Pharmaceuticals Ltd...
novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors. On January 7th, 2025, DualityBio and Avenzo announced that they have entered into an exclusive license agreement, pursuant to which Avenzo will...
said Dr. Stephanie Venn-Watson, Co-CEO of Seraphina Therapeutics. Dr. Venn-Watson was recently recognized as a 2025 CNBC Changemaker for her research on C15:0's essentiality and the discovery of Cellular Fragility Syndrome. In 2020, C15:0...
monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress hosted by the Parkinson & Movement Disorder Alliance in...
comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025. The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate...
(BLA) for this product is expected to be filed with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has already validated and accepted the marketing...
